Foa, Robin
 Distribuzione geografica
Continente #
NA - Nord America 577
EU - Europa 460
AS - Asia 124
OC - Oceania 5
AF - Africa 3
SA - Sud America 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 1172
Nazione #
US - Stati Uniti d'America 575
SE - Svezia 231
CN - Cina 102
IT - Italia 71
PL - Polonia 52
DE - Germania 45
FR - Francia 20
UA - Ucraina 11
IE - Irlanda 10
GB - Regno Unito 8
TR - Turchia 8
IN - India 7
AU - Australia 5
RU - Federazione Russa 4
FI - Finlandia 3
CA - Canada 2
CI - Costa d'Avorio 2
GR - Grecia 2
IR - Iran 2
JP - Giappone 2
AR - Argentina 1
BE - Belgio 1
BR - Brasile 1
CH - Svizzera 1
CY - Cipro 1
EG - Egitto 1
EU - Europa 1
ID - Indonesia 1
LT - Lituania 1
VN - Vietnam 1
Totale 1172
Città #
Chandler 193
Warsaw 52
Dearborn 45
Princeton 28
San Mateo 25
Beijing 24
Wilmington 23
Redwood City 22
Nanjing 20
Albany 16
Minneapolis 16
Florence 15
Nanchang 13
Boston 12
Houston 12
Norwalk 12
Kunming 11
Marseille 9
Ashburn 8
Hefei 8
Izmir 8
Cattolica 7
Fairfield 7
Chicago 6
Garden City 6
Changsha 5
Jacksonville 5
Seattle 5
Benalla 4
Redmond 4
Shenyang 4
Vicopisano 4
Falls Church 3
Fremont 3
Mountain View 3
Munich 3
Rome 3
Abidjan 2
Andover 2
Bari 2
Dublin 2
Gurgaon 2
Hebei 2
Jiaxing 2
Jinan 2
Lawrence 2
London 2
Moscow 2
Padova 2
Rivalta Di Torino 2
Turin 2
Verona 2
Woodbridge 2
Ardabil 1
Atlanta 1
Auburn Hills 1
Belo Horizonte 1
Berlin 1
Bremen 1
Brescia 1
Brussels 1
Buenos Aires 1
Busto Arsizio 1
Charlotte 1
Chengdu 1
Chennai 1
Cleveland 1
Como 1
Dong Ket 1
Edinburgh 1
Gossolengo 1
Helsinki 1
Hendon 1
Jakarta 1
Kish 1
Lanzhou 1
Malo 1
Mcallen 1
Milan 1
Naples 1
New Orleans 1
Nicosia 1
Ningbo 1
Nürnberg 1
Ottawa 1
Philadelphia 1
Pomigliano D'arco 1
Reston 1
Rochester 1
Rockland 1
Saint Petersburg 1
San Diego 1
Scotts Valley 1
Stockholm 1
Thonex 1
Tianjin 1
Tokyo 1
Torino 1
Trieste 1
Xian 1
Totale 723
Nome #
Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia 100
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors. A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (Gitmo) 81
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation 70
Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: Correlation with biologically-based risk stratification 58
Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia 57
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments. 54
Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma 54
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia 54
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 48
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study 44
HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia 42
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs 42
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study 41
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 41
Anti-HLA donor-specific antibodies in allogeneic stem cell transplantation: management and desensitization protocol 40
Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: Analysis of 1299 newly diagnosed cases 37
A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia 34
Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice. 33
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group 32
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 31
Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab 27
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 27
Prognostic impact and risk factors of infections in patients with chronic lymphocytic leukemia treated with ibrutinib 26
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus 24
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report 24
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study 23
Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment 22
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab 21
Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: A Campus CLL report 20
Totale 1207
Categoria #
all - tutte 3477
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3477


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/20186 0000 00 00 0060
2018/201948 0020 52 72 113142
2019/2020269 30333813 1532 3016 1918169
2020/202183 21137 1210 81 51185
2021/2022287 934736 376 232 1096234
2022/2023480 68763459 4168 1532 70890
Totale 1207